[A study on the relative factors for secondary parathyroidosis and renal osteodystrophy in long-term hemodialysis patients].

The authors classified sixty chronic renal failure (CRF) patients receiving hemodialysis (HD) treatment into four groups for clinical study. Forty patients received HD for more than five years and the remaining twenty patients received HD for less than two years. These two groups were further divided into two subgroups according to whether they took Rocaltrol or not. The levels of parathyroid hormone (PTH), calcitonin (CT), alkaline phosphatase (AKP) and bone X-ray were studied in each patient. The results showed: the levels of PTH and CT were obviously increased in all the patients. The levels of PTH and CT were higher in the patients having received HD for more than five years than those for less than two years. They were also higher in patients who had not taken Rocatrol than those who had. Ninety-five percent of the patients having received HD for more than five years had renal osteodystrophy (ROD) without receiving Rocaltrol treatment, while only sixty-five percent of the patients developed ROD with Rocatrol treatment. The longer the HD time, the higher the ROD incidence. The cause, prevention and treatment of ROD were discussed.